What are Cardiovascular Diseases (CVD)?
Cardiovascular diseases (CVDs) is the name for the group of disorders of heart and blood vessels. CVDs include hypertension (high blood pressure), coronary heart disease (heart attack), cerebrovascular disease (stroke), peripheral vascular disease, heart failure, heart valve disease and cardiomyopathies.
Why are CVDs a burden?
Cardiovascular diseases are the leading cause of death in Europe and a major cause of disability.
Preventing, detecting and diagnosing these conditions early – and managing them efficiently when they occur – is essential to keeping citizens of all ages out of hospital and in good health, while making efficient use of healthcare resources.
This is why the medical technology industry has aligned to promote a common call to action to prioritise CVDs in Europe.
How medical technologies help to reduce the CVD burden:
High-quality medical technologies are central to Europe’s fight against CVDs and can be found everywhere, e.g. :
– the blood tests that identify patients with high cholesterol, high risk of heart attack and heart failure
– the modern imaging devices that detect narrowing of the arteries
– the small cardiac implants such as pacemakers, defibrillators and trans-catheter technologies
– the implantable cardiac monitors and associated home monitoring solutions
– the minimally-invasive heart valve and stent procedures that improve clinical, procedural and patient outcomes, while reducing associated costs and recurrence
“As Chair of MedTech Europe’s Cardiovascular Sector Group, I look forward to working in partnership with authorities and stakeholders to reduce the burden of cardiovascular disease that weighs heavily on both healthcare systems and countless patients.”
Jean-Luc Lemercier, Chair Cardiovascular Sector Group, MedTech Europe
What we believe the EU can do:
EU Member States are responsible for the delivery of health and social care to patients. However, they face challenges that could benefit from coordinated action at EU level. There are actions we believe the EU could support to ensure that people live longer, healthier lives and continue to contribute to society:
1. Better understand the impact and burden of CVD on society
2. Improve patients’ quality of life
3. Recognize technologies for their clinical and economic value by fostering innovation
We believe strongly that constructive, collaborative partnerships with patients, governments and payers are needed to go even further to help alleviate Europe’s CVD burden once and for all.